A Phase II clinical trial of Tarceva(Erlotinib), Gemcitabine and Oxaliplatin combination chemotherapy in previously untreated Patients With locally advanced unresectable or metastatic Pancreatic Cancer.

Trial Profile

A Phase II clinical trial of Tarceva(Erlotinib), Gemcitabine and Oxaliplatin combination chemotherapy in previously untreated Patients With locally advanced unresectable or metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms GEMOX-T
  • Most Recent Events

    • 02 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Feb 2013 Planned End Date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 20 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top